In , Torrent Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +12.6% relative strength. Fundamentals: Average. On a 12-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Apr 18, 2026
What: JB Pharma Stake: 48.8%
Impact: INR 400-450 Cr synergy
“Following the acquisition of controlling interest of 48.8% in the company, our priority now is to ensure continuity in business operations.”
What: GLP-1 Launch: Next financial year
“10% to 15% of Sema would be a material opportunity and would move the needle for Torrent.”
What: EBITDA Margin: 32.9%
“Operating EBITDA at INR 1,088 crores, grew by 19%, and operating EBITDA margin stands at 32.9%.”
What: New Markets: $50 million targets
“So, four large markets like India, Brazil, Germany, US and we are preparing future large markets like Russia, then Mexico, then the Philippines.”
What: India Growth vs IPM: 14% vs 10%
“India revenue at INR 1,798 crores, registered a growth of 14%. As per the AIOCD Pharma Track market data, the IPM growth for the quarter was 10%.”
What: Brazil Revenue Growth of 27%
“Our 2 largest branded markets, India and Brazil, each continue to deliver healthy double-digit growth. India business grew at 14% and Brazil grew at 27%.”
What: 7,000 → 7,100
“Yes, that's correct. It will be just over 7000. So, maybe close to 7100. And as of now, we see maybe some additional visibility in the next coming year.”
Earnings deceleration risks from management commentary
Trigger: The supplier is caught up in regulatory issues involving EMA and FDA interactions.
Impact: PAT impact: 6% revenue decline in Germany
Management view: Working on alternate suppliers (3-4 quarters) and moving products to own facilities.
Monitor: regulatory
Trigger: Currency fluctuations leading to hedging losses.
Impact: PAT impact: INR 45 crores
Management view: Not explicitly detailed beyond booking the loss.
Monitor: fx
Trigger: Patent expires in March but litigation creates uncertainty on launch timing.
Management view: Waiting for clarity on when the market can form.
Monitor: litigation
Trigger: Competitive intensity from multiple players entering the market.
Impact: PAT impact: 45-50% price erosion expected
Management view: Targeting 15% market share despite erosion.
Monitor: commodity
Key quotes from recent conference calls
“We are on track to continue expansion to 7,000 reps by the end of the financial year. [Previous Field Force Expansion guidance]”
“We have also received SEBI approval on launching the minimum tender offer, and we should be completing that by December 15th. [Previous JB Pharma Acquisition Timeline guidance]”
“So, broadly, I would say that our synergy number is looking like INR 400 crores to INR 450 crores over the next 2 to 3 years. [Initiative: JB Pharma Integration]”
“So, the first milestone we are looking to cross is $200 million per year. And hopefully next year we will do that. [Initiative: US Business Scale-up]”
Headline numbers from the latest earnings call
Revenue
INR 3,303 crores
Why: Growth was driven by healthy double-digit performance in branded markets like India and Brazil, alongside a 19% increase in the U.S. business.
Revenue remained flat sequentially at INR 3,303 crores but showed strong year-on-year expansion.
EBITDA
INR 1,088 crores
Why: The margin expansion was supported by robust performance in branded markets which accounted for roughly 75% of overall revenues.
EBITDA margins improved slightly from 32.8% in Q2 to 32.9% in Q3.
Other Highlights
• India business grew at 14% and Brazil grew at 27% in Q3.
• Acquired controlling stake of 46.39% in JB Pharma on 21st January.
• Curatio business grew at 27% in Q3 and YTD 9 months.
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
ANDAs Filed (Annual Target)
4-5 ANDAs
Why: Ramping up US investments after a dry spell.
R&D as % of Sales
5-5.5%
Why: Increased investment in US pipeline development.
India Revenue % of Total
54.4%
Why: India revenue of 1,798 Cr on total of 3,303 Cr.
Brazil Revenue Growth (Constant Currency)
10%
Why: Secondary sales grew at 13% while primary was 10%.
Field Force Strength
6,900
Why: Expansion into chronic and sub-chronic divisions.
Net Debt
INR 880 crores
Why: Impacted by GST implementation credit period extensions and acquisition funding.
US Quarterly Revenue
$36 million
Why: Growth coming from new launches and increased purchase volume.
Brazil Pipeline Molecules
60 molecules
Why: Molecules awaiting approval at ANVISA.
Forward-looking targets from management for FY26-FY27
OPM Guidance
33%
Capex Plan
₹300 Cr
Expect India business to continue outperforming market growth.
Scope to bring JB's margin closer to base business margin.
INR 300 crores
Maintenance and growth capex
Continue above-market volume growth.
Guidance Changes
Field Force Target: 7,000 → 7,100
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +18% | +11% | Accelerating |
| PAT (Net Profit) | +26% | +35% | Stable |
| OPM | 33.0% | 0 bps | Expanding |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Torrent Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
Torrent Pharmaceuticals Ltd's profit is growing with an stable trend.
Torrent Pharmaceuticals Ltd's revenue growth trend is accelerating.
Torrent Pharmaceuticals Ltd's operating margin is expanding.
Torrent Pharmaceuticals Ltd's long-term compounding rates
Torrent Pharmaceuticals Ltd's earnings growth is stable with positive momentum on a sequential basis.
Torrent Pharmaceuticals Ltd's trailing twelve month (TTM) performance
Torrent Pharmaceuticals Ltd appears undervalued based on our fair value analysis.
Torrent Pharmaceuticals Ltd's current PE ratio is 64.3x.
Torrent Pharmaceuticals Ltd's current PE is 64.3x.
Torrent Pharmaceuticals Ltd's price-to-book ratio is 17.5x.
Torrent Pharmaceuticals Ltd is rated Average with a fundamental score of 59.96/100. This score is calculated from objective financial metrics
Torrent Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
Torrent Pharmaceuticals Ltd's return ratios over recent years
Torrent Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
Torrent Pharmaceuticals Ltd's current dividend yield is 0.73%.
Torrent Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
Torrent Pharmaceuticals Ltd's promoter holding has remained stable recently.
Torrent Pharmaceuticals Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
Torrent Pharmaceuticals Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
Torrent Pharmaceuticals Ltd has 7 key growth catalysts identified from recent earnings analysis
Torrent Pharmaceuticals Ltd has 4 key risks worth monitoring
In Q3 FY26, Torrent Pharmaceuticals Ltd's management highlighted
Torrent Pharmaceuticals Ltd's management has provided the following forward guidance for FY26-FY27
Torrent Pharmaceuticals Ltd's most important sub-sector-specific KPIs from the latest concall
Based on quantitative research signals, here is why Torrent Pharmaceuticals Ltd may be worth studying
Torrent Pharmaceuticals Ltd investment thesis summary:
Torrent Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
